| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | 0.02 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.015 | 0.9 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |